Literature DB >> 17926644

Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study.

José A Girón-González1, Francisco Brun, Alberto Terrón, Antonio Vergara, Ana Arizcorreta.   

Abstract

OBJECTIVE: To define the course of HIV-HCV-coinfected patients with compensated and decompensated liver cirrhosis and to investigate the survival and the risk factors for death. PATIENTS AND METHODS: Ninety-two HIV-infected patients with HCV-related cirrhosis (50 of them without and 42 with previous decompensations) were prospectively followed up during a median period of 20 months. Clinical, biochemical, virological and immunological factors were analysed. Multivariate analyses were performed of those factors associated with decompensations and mortality.
RESULTS: There were 168 readmissions due to liver-disease-related causes. A Child-Pugh index > or =6 in those without previous decompensations (hazard ratio [HR] 7.94, 95% confidence interval [CI] 1.59-39.58; P = 0.014), and Child-Pugh index > or =9 (HR 2.68, 95% CI 1.13-6.33; P = 0.003) and absence of HAART (HR 0.44, 95% CI 0.19-0.98; P = 0.048) in those with previous decompensations were independently associated with decompensation during the follow up. There were 27 deaths, 22 of them attributable to liver disease. Independent factors associated with liver-related mortality were a Child-Pugh index > or =9 (HR 6.24, 95% CI 2.31-16.85; P < 0.001), progression of Child-Pugh index during the follow up (HR 4.27, 95% CI 1.54-11.80; P = 0.008), more than one decompensation (HR 24.25, 95% CI 7.27-40.45; P < 0.001) and absence of HAART (HR 0.35, 95% CI 0.12-0.98; P = 0.002).
CONCLUSIONS: Evolution from compensated to decompensated cirrhosis and death is influenced by markers of liver function and the absence of HAART. The importance of this last element must be adequately stressed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17926644     DOI: 10.1177/135965350701200605

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  10 in total

Review 1.  Hepatitis C virus-HIV-coinfected patients and liver transplantation.

Authors:  Ani A Kardashian; Jennifer C Price
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

2.  Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.

Authors:  Benjamin P Linas; Angela Y Wong; Bruce R Schackman; Arthur Y Kim; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2012-04-04       Impact factor: 9.079

Review 3.  Virologic and immunologic aspects of HIV-hepatitis C virus coinfection.

Authors:  Kara W Chew; Debika Bhattacharya
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

4.  Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection.

Authors:  Daniel S Fierer; Douglas T Dieterich; M Isabel Fiel; Andrea D Branch; Kristen M Marks; Dahlene N Fusco; Ricky Hsu; Davey M Smith; Joshua Fierer
Journal:  Clin Infect Dis       Date:  2012-12-21       Impact factor: 9.079

Review 5.  Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity.

Authors:  Mercedes Márquez; Clotilde Fernández Gutiérrez del Álamo; José Antonio Girón-González
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 6.  HCV and HIV co-infection: mechanisms and management.

Authors:  Jennifer Y Chen; Eoin R Feeney; Raymond T Chung
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-02-18       Impact factor: 46.802

7.  CD4 recovery on antiretroviral therapy is associated with decreased progression to liver disease among hepatitis C virus-infected injecting drug users.

Authors:  Jeffrey P Anderson; C Robert Horsburgh; Paige L Williams; Eric J Tchetgen Tchetgen; David Nunes; Deborah Cotton; George R Seage
Journal:  Open Forum Infect Dis       Date:  2015-02-28       Impact factor: 3.835

8.  The hepatitis C cascade of care: identifying priorities to improve clinical outcomes.

Authors:  Benjamin P Linas; Devra M Barter; Jared A Leff; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Arthur Y Kim; Bruce R Schackman
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.752

9.  Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation.

Authors:  Giovanni Cenderello; Stefania Artioli; Claudio Viscoli; Ambra Pasa; Mauro Giacomini; Barbara Giannini; Chiara Dentone; Laura Ambra Nicolini; Giovanni Cassola; Antonio Di Biagio
Journal:  Clinicoecon Outcomes Res       Date:  2015-12-31

10.  Antiretroviral therapy and liver disease progression in HIV and hepatitis C co-infected patients: a systematic review and meta-analysis.

Authors:  Alexis Llewellyn; Mark Simmonds; Will L Irving; Ginny Brunton; Amanda J Sowden
Journal:  Hepatol Med Policy       Date:  2016-08-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.